Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares stood at 4.56 million during the last session, with the company’s beta value hitting 0.77. At the close of trading, the stock’s price was $13.50, to imply a decrease of -4.73% or -$0.67 in intraday trading. The STOK share’s 52-week high remains $16.40, putting it -21.48% down since that peak but still an impressive 75.19% since price per share fell to its 52-week low of $3.35. The company has a valuation of $625.05M, with an average of 4.67 million shares in intraday trading volume over the past 10 days and average of 855.99K shares over the past 3 months.
Stoke Therapeutics Inc (NASDAQ:STOK) trade information
After registering a -4.73% downside in the last session, Stoke Therapeutics Inc (STOK) has traded red over the past five days. The stock hit a weekly high of 16.40, dropping -4.73% in its intraday price action. The 5-day price performance for the stock is 125.38%, and 69.60% over 30 days. With these gigs, the year-to-date price performance is 156.65%. Short interest in Stoke Therapeutics Inc (NASDAQ:STOK) saw shorts transact 3.55 million shares and set a 12.07 days time to cover.
Stoke Therapeutics Inc (STOK) estimates and forecasts
Looking at statistics comparing Stoke Therapeutics Inc share performance against respective industry, we note that the company has underperformed competitors. Stoke Therapeutics Inc (STOK) shares are 246.15% up over the last 6 months, with its year-to-date growth rate lower than industry average at 4.62% against 13.00%. Revenue is forecast to shrink -17.00% this quarter before jumping 18.80% for the next one. The rating firms project that company’s revenue will grow 40.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is $3.21 million. Meanwhile, for the quarter ending Jun 2024, a total of 7 analyst(s) estimate revenue growth to $3.36 million.Earnings reports from the last fiscal year show that sales brought in $5.15 million and -$2.48 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -37.70% before dropping -235.40% in the following quarter.
STOK Dividends
Stoke Therapeutics Inc has its next earnings report out between May 02 and May 06. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Stoke Therapeutics Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Stoke Therapeutics Inc (NASDAQ:STOK)’s Major holders
Stoke Therapeutics Inc insiders hold 5.19% of total outstanding shares, with institutional holders owning 98.01% of the shares at 103.38% float percentage. In total, 98.01% institutions holds shares in the company, led by Skorpios Trust. As of Jun 29, 2023, the company held over 14.44 million shares (or 32.61% of shares), all amounting to roughly $153.54 million.
The next major institution holding the largest number of shares is RTW Investments LP with 4.39 million shares, or about 9.91% of shares outstanding. As of the market price on Jun 29, 2023, these shares were worth $46.67 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Stoke Therapeutics Inc (STOK) shares. Going by data provided on Jun 29, 2023, Vanguard Total Stock Market Index Fund holds roughly 1.03 million shares. This is just over 2.32% of the total shares, with a market valuation of $10.94 million. Data from the same date shows that the other fund manager holds a little less at 0.63 million, or 1.42% of the shares, all valued at about 3.54 million.
